Estrella Immunopharma’s (ESLA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Estrella Immunopharma (NASDAQ:ESLA) in a report issued on Monday,Benzinga reports. They currently have a $8.00 target price on the stock.

A number of other research firms have also weighed in on ESLA. Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Wednesday, January 28th. Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Estrella Immunopharma presently has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Performance

NASDAQ ESLA opened at $1.42 on Monday. The business has a fifty day moving average price of $1.40 and a 200 day moving average price of $1.44. The company has a market cap of $53.63 million, a P/E ratio of -4.18 and a beta of 0.55. Estrella Immunopharma has a one year low of $0.73 and a one year high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last released its earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06.

Institutional Trading of Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC boosted its holdings in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 8.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 109,808 shares of the company’s stock after acquiring an additional 8,318 shares during the period. Geode Capital Management LLC owned 0.29% of Estrella Immunopharma worth $171,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.